BC-3781

DRUG2 trials

Sponsors

Nabriva Therapeutics AG

Conditions

Bacterial InfectionsHealthyInfection

Phase 1

A Study to Assess Mass Balance Recovery, Metabolite Profile and Identification of IV and Oral 14C-BC-3781

CompletedNCT03131141

Nabriva Therapeutics AGHealthy

Start: 2017-01-08End: 2018-03-30Updated: 2018-04-03

Phase 2

Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

CompletedNCT01119105

Nabriva Therapeutics AGBacterial Infections, Infection

Start: 2010-05-31End: 2011-02-03Updated: 2020-11-17

Related Papers

Population Pharmacokinetic Analyses for BC-3781 Using Phase 2 Data from Patients with Acute Bacterial Skin and Skin Structure Infections

Antimicrobial Agents and Chemotherapy2014-10-2830 citations